Pathobiology of liver fibrosis: a translational success story

• Published in: Gut Vol. 64; no. 5; pp. 830 - 841
• Main Authors: Lee, Youngmin A, Wallace, Michael C, Friedman, Scott L
• Format: Journal Article Book Review
• Language: English
• Published: England BMJ Publishing Group LTD 01.05.2015
• Subjects: Chronic illnesses; Clinical trials; Clinical Trials as Topic - methods; Drug Discovery - methods; Family medical history; Fibroblasts; Gastrointestinal surgery; Growth factors; Hepatic Stellate Cells - physiology; Hepatitis; Hepatitis B virus; Humans; Liver cancer; Liver cirrhosis; Liver Cirrhosis - drug therapy; Liver Cirrhosis - pathology; Liver diseases; Mortality; Patient Selection; Rodents; Stem cells; Translational Medical Research - methods; FATTY LIVER; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELL; CIRRHOSIS; HEPATIC FIBROSIS
• ISSN: 0017-5749; 1468-3288
• DOI: 10.1136/gutjnl-2014-306842

Reversibility of hepatic fibrosis and cirrhosis following antiviral therapy for hepatitis B or C has advanced the prospect of developing antifibrotic therapies for patients with chronic liver diseases, especially non-alcoholic steatohepatitis. Mechanisms of fibrosis have focused on hepatic stellate cells, which become fibrogenic myofibroblasts during injury through ‘activation’, and are at the nexus of efforts to define novel drug targets. Recent studies have clarified pathways of stellate cell gene regulation and epigenetics, emerging pathways of fibrosis regression through the recruitment and amplification of fibrolytic macrophages, nuanced responses of discrete inflammatory cell subsets and the identification of the ‘ductular reaction’ as a marker of severe injury and repair. Based on our expanded knowledge of fibrosis pathogenesis, attention is now directed towards strategies for antifibrotic therapies and regulatory challenges for conducting clinical trials with these agents. New therapies are attempting to: 1) Control or cure the primary disease or reduce tissue injury; 2) Target receptor-ligand interactions and intracellular signaling; 3) Inhibit fibrogenesis; and 4) Promote resolution of fibrosis. Progress is urgently needed in validating non-invasive markers of fibrosis progression and regression that can supplant biopsy and shorten the duration of clinical trials. Both scientific and clinical challenges remain, however the past three decades of steady progress in understanding liver fibrosis have contributed to an emerging translational success story, with realistic hopes for antifibrotic therapies to treat patients with chronic liver disease in the near future.